AACC Notes: Biomarkers for Cardiovascular Risk-hsCRP
Last week's Plenary Session from the AACC featured Paul Ridker.MD,MPH from Brigham and Women's Hospital ,Boston,MA speaking about Inflammation,hsCRP and Cardiovascular Prevention. The session reviewed data from the JUPITER trial for the use of statins in primary cardiovascular prevention. Dr....
Novartis(NVS) and Pathwork Dx Collaborate on Biomarkers
The Wall Street Journal reported on Friday that Novartis (NVS) will collaborate with Pathwork Diagnostics on the development of biomarkers across a range of cancer types that would capitalize on the trend to "match patients with the right medicines". Pathwork, a venture funded Company in...
“AACC Effect” Rally Rolls On: Abaxis(ABAX),GenProbe (GPRO),and Quidel (QDEL)
The intersection of good earnings and a strong AACC showing boosted Diagnostic stocks this week with the following big movers today on earnings reports: Abaxis (ABAX) $20.81 up $13.7%,GenProbe (GPRO) $45.85 up 8.14%,Neogen (NEOG) $29.85 up 3.4% and Quidel (QDEL) $12.34 up 3.5%.Bruker was also...
AACC Notes-Diagnostic Stocks and Rayno Model Portfolio
Here are some brief notes from our visit to the AACC in Anaheim and recent earnings reports. Rayno Diagnostic and Tools Portfolio Abaxis (ABAX)-under review- and Quidel (QDEL) report today.We added Quidel to our model portfolio on 6/16 at $12.40.The stock is trading at around $12 maybe...
AACC Meeting: Buzz Coming to Fuel the Rally In Diagnostic Stocks
The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors . A stock rally in the sector was ignited last week by earnings announcements from four major mid-cap players and new product and...